Items Tagged ‘CLL’

July 11th, 2016

Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia

By

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Chronic lymphocytic leukemia is the most common form of adult leukemia. The American […]

View full entry

Tags: 2016, asco, Bruton’s tyrosine kinase, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, CLL, early-stage, ibrutinib, imbruvica, Leukemia, News


March 23rd, 2016

FDA Approves Imbruvica for First Line Treatment of Chronic Lymphocytic Leukemia

By

Learn more about other FDA Approvals for CLL here. Find more information on CLL here. The US Food and Drug Administration (FDA) approved Imbruvica® (ibrutinib) for first-line use in patients with chronic lymphocytic leukemia (CLL). The approval means that there is, for the first time, a chemotherapy-free option for initial treatment of CLL.1 Chronic lymphocytic […]

View full entry

Tags: chemotherapy-free option, Chronic Lymphocytic Leukemia, CLL, first-line use, ibrutinib, imbruvica, Leukemia, News


February 29th, 2016

Arzerra® Approved as Maintenance Therapy for Advanced CLL

By

The United States Food and Drug Administration (FDA) has approved Arzerra® (ofatumumab) as maintenance therapy for the treatment of advanced chronic lymphocytic leukemia (CLL). This product is already approved to treat patients with CLL who have not received prior therapy, or whose CLL has stopped responding to prior therapies. CLL is a type of cancer […]

View full entry

Tags: arzerra, B-cells, biologic agent, CD-20, Chronic Lymphoblastic Leukemia, chronic lymphocytic, CLL, fda, Leukemia, News, ofatumumab, PROLONG


December 31st, 2015

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings

By

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH) Annual Meeting, in Orlando, December 5-8, made it increasingly clear that new discoveries […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, all, AML, ASH, blood cancer, CAR T, Chronic Lymphocytic Leukemia, CLL, fda, Leukemia, Lymphoma


December 17th, 2015

ACP-196 Bruton’s Tyrosine Kinase Inhibitor Safe and Effective for Chronic Lymphocytic Leukemia

By

Clinical results published in the New England Journal of Medicine show that the new drug acalabrutinib (ACP-196) is well tolerated and yields high response rates that are durable in patients with chronic lymphocytic leukemia (CLL). CLL is characterized by the production of atypical lymphocytes. Lymphocytes are specialized immune cells that exist in two forms: B- […]

View full entry

Tags: Acalabrutinib, ACP-196, Chronic, Chronic Lymphocytic Leukemia, CLL, Leukemia, News


November 18th, 2015

Zydelig® Combined with Treanda and Rituxan Appears Promising in Treatment of Chronic Lymphocytic Leukemia

By

Following the recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc today announced that its Phase 3 clinical study evaluating Zydelig® (idelalisib) added to standard therapy in previously-treated chronic lymphocytic leukemia (CLL) patients will be unblinded early. The DMC recommendation is based upon a predefined interim analysis indicating a benefit in patients receiving […]

View full entry

Tags: Chronic Lymphocytic Leukemia, CLL, News, Phase III clinical trial, rituxan, Treanda, zydelig


January 15th, 2015

FDA Approves Gazyva® (Obinutuzumab) Supplemental Biologics License Application with New Data in Previously Untreated Chronic Lymphocytic Leukemia

By

Genentech announced that the U.S. Food and Drug Administration (FDA) approved a supplemental biologics license application (sBLA) for Gazyva in combination with chlorambucil chemotherapy in people with previously untreated chronic lymphocytic leukemia (CLL). Gazyva was the first medicine approved with the FDA’s Breakthrough Therapy Designation, and was approved for use in combination with chlorambucil in […]

View full entry

Tags: Chronic Lymphocytic Leukemia, CLL, gayza, Leukemia, News, obinutuzumab


September 10th, 2014

Promising Activity of Imbruvica Plus Rituxan in High-Risk CLL

By

Researchers from MD Anderson Cancer Center recently reported in the journal The Lancet Oncology that the combination of Imbruvica® (ibrutinib) and Rituxan® (rituximab) showed promising activity in the management of patients with high-risk chronic lymphocytic leukemia (CLL). CLL is characterized by the production of atypical lymphocytes. Lymphocytes are specialized immune cells that exist in two forms: B- and […]

View full entry

Tags: Chronic Lymphocytic Leukemia, CLL, ibrutinib, imbruvica, Leukemia, News


August 25th, 2014

FDA Approves New Treatment Options for Low Grade Lymphomas and Chronic Lymphocytic Leukemia

By

Gilead Sciences has confirmed FDA approval of Zydelig (idelalisib) for relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL). Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells of the lymph system. The lymph system includes the spleen, thymus, tonsils, bone marrow, lymph nodes, and circulating immune […]

View full entry

Tags: Chronic Lymphoblastic Leukemia, CLL, Leukemia, News, zydelig


July 21st, 2014

Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment

By

A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment, which involves extracting specific white blood cells from a patient and modifying them before infusion back into the patient, is currently involved in a phase […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, cd19, Chronic Lymphocytic Leukemia, CLL, Indolent/Low Grade Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, News, Non-Hodgkin's Lymphoma


June 19th, 2014

Imbruvica Found to Extend Survival in CLL Patients

By

Researchers reported at the annual American Society of Clinical Oncology meeting in Chicago that chronic lymphoid leukemia (CLL) patients treated with Imbruvica™ (ibrutinib) showed improved survival when compared to those treated with Arzerra® (ofatumumab). Because the Imbruvica group showed a significant advantage in progression-free survival at an interim point, the trial was halted and Arzerra […]

View full entry

Tags: arzerra, asco, Chronic Lymphocytic Leukemia, CLL, ibrutinib, imbruvica, Leukemia, News